肠道菌群在心血管疾病中的作用及其机制研究进展  

Research progress on role and mechanism of gut microbiota in cardiovascular diseases

作　　者：胡娟[1] 汪星辉[1] 高杉[2] 孟祥云[1] HU Juan;WANG Xing-hui;GAO Shan;MENG Xiang-yun(Dept of Pharmacy, the Second People’s Hospital of Hefei, Affiliated Hefei Hospital of Anhui Medical University,Hefei 230011, China;Dept of pharmacology, School of Basic Medicine , Anhui Medical University, Hefei 230032, China)

机构地区：[1]合肥市第二人民医院(安徽医科大学附属合肥医院)药学部,安徽合肥230011 [2]安徽医科大学基础医学院药理教研室,安徽合肥230032

出　　处：《中国药理学通报》2019年第11期1496-1500,共5页Chinese Pharmacological Bulletin

基　　金：国家自然基金项目(No 81873126);重大新药创制资助课题(No 2017ZX09301012);合肥市第二人民医院院级科研项目(No 20194551)

摘　　要：肠道菌群(gut microbiota,GM)是细菌、真菌、古生菌、病毒和原生动物的集合体,数量大、种类多。它们栖息在人体肠道中,影响人类的健康和疾病。GM与宿主之间有着密切的信息交换,如免疫防御、神经系统调节,特别是在新陈代谢方面发挥的重要作用,维持自身与宿主之间的动态平衡,也与心血管疾病(cardiovascular diseases,CVDs)有着密切的联系。临床资料和动物实验均揭示了GM失调,可加速CVDs的发展,其产生的生物活性代谢物可以影响宿主的生理作用。该文旨在系统阐述GM及其代谢产物与CVDs之间的联系,并综述可能作用机制的最新研究进展,调控GM有望成为CVDs新的治疗靶点。Gut microbiota (GM) of human hosts is the community of microorganisms living in small and, mainly, large intestine of humans. It is composed of various species, including bacteria, fungi, archaea, viruses and protozoa. Accumulating evidence has linked changes in the composition or metabolic profiles of the microbiota with human diseases, such as disorders of the cardiovascular spectrum. Clinical data and animal experiments in recent years have revealed that GM imbalance can worsen the development of cardiovascular diseases (CVDs). Also, the physiological state of the host is also influenced by its bioactive metabolites. In this review, we systematically elucidate the relationship between CVDs and GM and its metabolites, and further review the latest research progress on the possible mechanism of action. It is expected that GM regulation can be a new therapeutic target for CVDs.

关 键 词：肠道菌群 心血管疾病 代谢物 氧化应激 炎症反应 代谢紊乱 

分 类 号：R322.45[医药卫生—人体解剖和组织胚胎学] R349.1[医药卫生—基础医学]